Fig. 3From: Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective studyKaplan-Meier estimates of progression-free survival 2 (PFS2). A PFS2 in 120 patients. B PFS2 in patients with PD-L1 TPS < 1%. C PFS2 in patients with PD-L1 TPS 1–49%. D PFS2 in patients with PD-L1 TPS ≥50%Back to article page